Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R110
- Development stage
- Preclinical
- Lead developer
- University of Florida
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
R110 is an engineered live biotherapeutic product (LBP) consisting of a food-grade *Lactococcus lactis* strain genetically modified to express the surface layer protein A (SlpA) derived from *Lactobacillus acidophilus*. Developed for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, R110 functions by modulating the host immune repertoire to suppress intestinal inflammation. Upon oral administration, the SlpA protein delivered by the bacteria induces the expression of interleukin-27 (IL-27) by myeloid cells. This induction leads to a synchronous increase in interleukin-10 (IL-10) and the transcription factor c-Maf in T cells, promoting an anti-inflammatory environment. Preclinical studies in murine models of colitis and human dendritic cell assays have demonstrated its potential to mitigate symptoms and regulate gene expression associated with IBD.
- Other names
- SlpA-expressing Lactococcus lactisLactococcus lactis R110
02
Targets
IL10 (Interleukin-10)IL-27 (Interleukin-27)
Beyond the preview
Go deeper on R110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R110.